6. RIFERIMENTI BIBLIOGRAFICI
Bartenschlager R. and Lohmann V. (2000) Replication of hepatitis C virus. Journal of General Virology 81: 1631-1648
Bartosch B., Dubuisson J. and Cosset F.-L. (2003) Infectious hepatitis C virus
pseudo-particles containing functional E1–E2 envelope protein complexes.
The Journal of Experimental Medicine 197(5): 633–642
Bigornia L., Lockridge K.M. and Sparger E.E. (2001) Construction and in vitro
characterization of attenuated feline immunodeficiency virus long terminal repeat mutant viruses. Journal of Virology 75(2): 1054-1060
Bouard D., Alazard-Dany N. and Cosset F.-L. (2009) Viral vectors: from virology
to transgene expression. British Journal of Pharmacology 157(2): 153–165
Boulant S., Vanbelle C., Ebel E., Penin F. and Lavergne J.-P. (2005) Hepatitis C
virus core protein is a dimeric alpha-helical protein exhibiting membrane protein features. Journal of Virology 79(17): 11353-11365
Bowen D.-G., and Walker C.-M. (2005) Adaptive immune responses in acute
and chronic hepatitis C virus infection. Nature 436(7053): 946–952
Cocquerel L., Voisset C. and Dubuisson J. (2006) Hepatitis C virus entry:
potential receptors and their biological functions. Journal of General Virology 87: 1075–1084
Connolly J.B. (2002) Lentiviruses in gene therapy clinical research. Gene Therapy 9(24): 1730-1734
Curran M.A., Kaiser S.M., Achacoso P.L. and Nolan G.P (2000) Efficient
transduction of nondividing cells by optimized feline immunodeficiency virus vectors. Molecular therapy: the journal of the American Society of Gene
Therapy 1(1): 31-38
Day C.L., Lauer G.M., Robbins G.K., McGovern B., Wurcel A.G., Gandhi R.T., Chung R.T. and Walker B.D. (2002) Broad specificity of virus-specific CD4+
T-helper-cell responses in resolved hepatitis C virus infection. Journal of Virology 76(24): 12584-12595
Dhillon R., Rossi S. and Herrine S. (2008) Pegylated interferon 2a and 2b in
combination with ribavirin for the treatment of chronic hepatitis C in HIV infected patients. Therapeutics and Clinical Risk Management 4(4): 789–796
Drummer H.E., Maerz A. and Poumbourios P. (2003). Cell surface expression of
functional hepatitis C virus E1 and E2 glycoproteins. FEBS Letters 546(2-3): 385–390
Dubuisson J. (2007) Hepatitis C virus proteins. World Journal of Gastroenterology 13(17): 2406-2415
Egger D., Wölk B., Gosert R., Bianchi L., Blum H.E., Moradpour D. and Bienz K. (2002) Expression of hepatitis C virus proteins induces distinct membrane
alterations including a candidate viral replication complex. Journal of Virology 76(12): 5947-5984
Evans M. J., von Hahn T., TscherneD.M., SyderA.J, PanisM.,WölkB., Hatziioannou T., McKeatingJ.A., BieniaszP.D: and Rice C.M. (2007) Claudin-1 is a hepatitis C
virus co-receptor required for a late step in entry. Nature 446: 801–805
Farci P., Alter H.J., Wong D.C., Miller R.H:, Govindarajan S, Engle R., Shapiro M. and Purcell R.H (1994) Prevention of hepatitis C virus infection in chimpanzees
after antibody-mediated in vitro neutralization. Proceedings of the National Academy of Sciences of the U.S.A. 91(16): 7792–7796
Farci P.,Shimoda A., Coiana A., Diaz G., Peddis G.,. Melpolder J.C., Strazzera A.,Chien D.Y., Munoz S.J., Balestrieri A., Purcell R.H. and Alter H.J. (2000) The outcome of
acute hepatitis C predicted by the evolution of the viral quasispecies.
Science 288(5464): 339–344
Goutagny N., Fatmi A., De Ledinghen V., Penin F., Couzigou P., Inchauspe G. and Bain C. (2003) Evidence of viral replication in circulating dendritic cells
during hepatitis C virus infection. The Journal of Infectious Diseases 187(12): 1951-1958
Grakoui A., Hanson H.L. and Rice C.M. (2001). Bad time for Bonzo?
Experimental models of hepatitis C virus infection, replication, and pathogenesis. Hepatology 33(3): 489-495
Gremion C. and Cerny A. (2005) Hepatitis C virus and the immune system: a
concise review. Reviews in Medical Virology 15(4): 235–268
Griffin S.D., Beales L.P., Clarke D.S., Worsfold O., Evans S.D., Jaeger J., Harris M.P.and Rowlands D.J. (2003) The p7 protein of hepatitis C virus forms an ion
channel that is blocked by the antiviral drug, Amantadine. FEBS Letters 535(1-3): 34-8
Helle F., Goffard A., Morel V., Duverlie G., McKeating J., Keck Z.-Y., Foung S.,nPenin F., Dubuisson J. and Voisset C. (2007) The Neutralizing Activity of
Anti-Hepatitis C Virus Antibodies Is Modulated by Specific Glycans on the E2 Envelope Protein. Journal of Virology 81(16): 8101-8111
Hsu M., Zhang J., Flint M.., Logvinoff C., Cheng-Mayer C., Rice C. M. and McKeating J. A. (2003) Hepatitis C virus glycoproteins mediate pH-dependent cell entry
of pseudotyped retroviral particles. Proceedings of the National Academy of Sciences of the U.S.A 100: 7271–7276
Ishii S. and Koziel M.J. (2008) Immune responses during acute and chronic
infection with hepatitis C virus. Clinical Immunology 128(2): 133–147
Johnston J.C., Gasmi M., Lim L.E., Elder J.H., Yee J.K., Jolly D.J., Campbell K.P., Davidson B.L. and Sauter S.L. (1999) Minimum requirements for efficient
transduction of dividing and nondividing cells by feline immunodeficiency virus vectors. Journal of Virology 73(6): 4991-5000
Lavie M., Goffard A. and Dubuisson J.(2007) Assembly of a Functional HCV
Glycoprotein Heterodimer. Current Issues Molecular Biology 9(2): 71-86
Lesburg C.A., Cable M.B., Ferrari E., Hong Z., Mandarino A.F. and Weber P.C. (1999)
Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nature Structural Biology 6: 937-943 Levy S., Todd S.C. and Maecker H.T. (1998) CD81 (TAPA-1): a molecule
involved in signal transduction and cell adhesion in the immune system.
Annual Review of Immunology 16: 89-109
Logvinoff C, Major ME, Oldach D,. Logvinoff C., Major M.E., Oldach D., Heyward S., Talal A., Balfe P., Feinstone S.M., Alter H., Rice C.M. and McKeating J.A. (2004).
Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proceedings of the National Academy of Sciences of the U.S.A. 101(27): 10149–10154
Lundberg C., Björklund T., Carlsson T., Jakobsson J., Hantraye P., Déglon N. and Kirik D. (2008) Application of lentiviral vector for biology and gene therapy
of neurological disorders. Current Gene Therapy 8(6): 406-418
Mangeot P.E., Duperrier K., Nègre D., Boson B., Rigal D., Cosset F.L. and Darlix J.L. (2002) High levels of transduction of human dendritic cells with optimized
SIV vectors. Molecular therapy: the journal of the American Society of Gene
Therapy 5(3): 283-290
Mascola J.R., D'Souza P., Gilbert P., Hahn B.H., Haigwood N.L., Morris L., Petropoulos C.J., Polonis V.R., Sarzotti M. and Montefiori D.C. (2005)
Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. Journal of Virology. 79(16): 10103-10107
Matthews G.V. and Dore G.J. (2008) HIV and hepatitis C coinfection. Journal of gastroenterology and hepatology 23: 1000-1008
McLauchlan J. (2000) Properties of the hepatitis C virus core protein: a
structural protein that modulates cellular processes. Journal of viral hepatitis 7(1): 2-14
Orland J.R., Wright T.L. and Cooper S. (2001) Acute hepatitis C. Hepatology 33(2): 321–327
Owsianka A., Tarr A.W., Juttla V.S., Lavillette D., Bartosch B., Cosset F.L., Ball J.K. and Patel A.H. (2005) Monoclonal antibody AP33 defines a broadly
neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein.
Journal of Virology 79(17): 11095–11104
Pistello M., Bonci F., Zabogli E., Conti F., Freer G., Maggi F., Stevenson M. and Bendinelli M. Env-expressing autologous T-lymphocytes induce high level
neutralizing antibody and offer marked protection from lentivirus infection. Submitted
Ploss A., Evans M.J., Gaysinskaya V.A., Panis M., You H., de Jong Y.P. and Rice C.M. (2009) Human occludin is a hepatitis C virus entry factor required for
infection of mouse cells. Nature 457(7231): 882-886
Poeschla E.M., Wong-Staal F. and Looney D.J. (1998) Efficient transduction of
nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nature Medicine 4(3): 354-357
Polonis V.R., Brown B.K., Rosa Borges A., Zolla-Pazner S., Dimitrov D.S., Zhang M.Y., Barnett S.W., Ruprecht R.M., Scarlatti G., Fenyö E.M., Montefiori D.C., McCutchan F.E. and Michael N.L. (2008) Recent advances in the characterization of HIV-1
neutralization assay for standardized evaluation of the antibody response to infection and vaccination. Virology 375(2): 315-320
Roberts E.A. and Yeung L. (2002) Maternal-infant transmission of hepatitis C
virus infection. Hepatology 36(5 suppl 1): S106–S113
Rosen H.R. (2003) Hepatitis C pathogenesis: mechanisms of viral clearance
and liver injury. Liver Transplantation 9(11): S35-S43
Russell J.H. and Ley T.J. (2002) Lymphocyte-mediated cytotoxicity. Annual Review of Immunology 20: 323-370
Schmidt-Mende J., Bieck E., Hugle T., Penin F., Rice C.M., Blum H.E. and Moradpour D. (2001) Determinants for membrane association of the hepatitis C virus
RNA-dependent RNA polymerase. The Journal of Biological Chemistry 276(47): 44052–44063
Shimoike T., Minori S., Tani H., Matsuura Y. and Miyamura (1999) Interaction of
hepatitis C virus core protein with viral sense RNA and suppression of its translation. Journal of Virology 73(12): 9718-9725
Siapati E.K., Bigger B.W., Miskin J., Chipchase D., Parsley K.L, Mitrophanous K., Themis M., Thrasher A.J., and Bonnet D. (2005) Comparison of HIV- and
EIAV-based vectors on their efficiency in transducing murine and human hematopoietic repopulating cells. Molecular therapy: the journal of the
American Society of Gene Therapy 12(3): 537-46
Simmonds P., Bukh J., Combet C., Deleage G., Enomoto N., Feinstone S., Halfon P., Inchauspe G., Kuiken C., Maertens G., Mizokami M., Murphy D.G., Okamoto H., Pawlotsky J.M., Penin F., Sablon E., Shin-I T., Stuyver L.J., Thiel H.J., Viazov S., Weiner A.J.and Widell A. (2005) Consensus proposals for a unified system of
nomenclature of hepatitis C virus genotypes. Hepatology 42(4): 962-973
Sung V.M., Shimodaira S., Doughty A.L., Picchio G.R., Can H., Yen T.S., Lindsay K.L., Levine A.M., Lai M.M. (2003) Establishment of B-cell lymphoma cell lines
persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection. Journal of Virology 77(3): 2134-2146
Suzuki T, Ishii K., Aizaki H. and Wakita T. (2007) Hepatitis C viral life cycle. Advanced Drug Delivery Reviews 59(12): 1200–1212
Tan S.L. and Katze M.G. (2001) How hepatitis C virus counteracts the
interferon response: the jury is still out on NS5A. Virology 284(1): 1-12
Tedaldi E.M. (2005) New drug targets for HIV and hepatitis C virus
coinfection. Clinical Infectious Diseases 41(suppl1): S101–S104
Tellinghuisen T.L., Rice C.M. (2002) Interaction between hepatitis C virus
proteins and host cell factors. Current opinion in microbiology 5(4): 419-427 Thimme R., Oldach D., Chang K.M., Steiger C., Ray S.C. and Chisari F.V. (2001)
Determinants of viral clearance and persistence during acute hepatitis C virus infection. The Journal of Experimental Medicine 194(10): 1395-1406
Thomas C.E., Ehrhardt A. and Kay M.A. (2003) Progress and problems with the
use of viral vectors for gene therapy. Nature reviews. Genetics 4(5): 346-358 Voisset C., Op De Beeck A., Horellou P., Dreux M., Gustot T., Duverlie G., Cosset F.-L., Vu-Dac N., and Dubuisson J. (2006) High-density lipoproteins reduce the
neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry. Journal of General Virology 87: 2577–2581
Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzalez J.F., Salazar M.G., Kilby J.M., Saag M.S., Komarova N.L., Nowak M.A., Hahn B.H., Kwong P.D. and Shaw G.M. (2003) Antibody neutralization and escape by HIV-1. Nature 422:307–312.
Zeisel M.B., Fafi-Kremer S., Fofana I., Barth H., Stoll-Keller F., Doffoel M. and Baumert T.F. (2007) Neutralizing antibodies in hepatitis C virus infection.
